Financial reports

The Danish listing prospectus dated September 30 2020 (and information contained therein) which is available on this section of Orphazyme’s website is not intended for, and must not be accessed by, or distributed or disseminated, directly or indirectly, in whole or in part, to persons resident or physically present in the United States of America (including its territories and possessions, any state of the United States and the District of Columbia, the "United States") or any jurisdiction where to do so might constitute a violation of the local securities laws or regulations of such jurisdiction, and does not constitute an offer to sell or the solicitation of an offer to buy or acquire, any ordinary shares or other securities of Orphazyme.


Årsrapport 2023

Interim Report First Half 2023

Annual Report 2022
Remuneration Report 2022
Interim Report First Half 2022
Annual Report 2021
Remuneration Report 2021
Interim Report First Half 2021
Annual Report 2020
Remuneration Report 2020
Orphazyme Listing Prospectus September 30, 2020
Interim Report First Half 2020
Orphazyme Listing Prospectus March 16, 2020
Annual Report 2019
Interim Report First Half 2019
Annual Report 2018
Interim Report First Half 2018
Annual Report 2017
Prospectus 2017
Audited financial statements FY2016